Metraipolis › archive › dc_03e1d95a37ed

Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations — Europe PMC PMID:41306958

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41306958
DOI
10.3389/fimmu.2025.1684089
License (as archived)
solo-consultazione
Archived
2026-11-08T16:23:06.719Z
SHA-256 of the archived text
2f653554006a6fa0aeb070bd683247a63fbe9edda28485e4e69de771e309a69d
Stable URL of this page
https://metraipolis.com/documento/dc_03e1d95a37ed

How to cite

Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations — Europe PMC PMID:41306958 — Europe PMC (en), https://europepmc.org/article/MED/41306958 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_03e1d95a37ed (Metraipolis archive dc_03e1d95a37ed, sha256 2f653554006a6fa0aeb070bd683247a63fbe9edda28485e4e69de771e309a69d)
BibTeX
@misc{dc03e1d95a37ed,
  title = {Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations — Europe PMC PMID:41306958},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41306958},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_03e1d95a37ed; sha256 2f653554006a6fa0aeb070bd683247a63fbe9edda28485e4e69de771e309a69d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41306958. Agents can read the archived copy with the MCP tool read_document.